...
首页> 外文期刊>Jornal Brasileiro de Nefrologia >Evaluation of the 1000 renal transplants carried out at the University Hospital of the Botucatu Medical School (HCFMB) - UNESP and their evolution over the years
【24h】

Evaluation of the 1000 renal transplants carried out at the University Hospital of the Botucatu Medical School (HCFMB) - UNESP and their evolution over the years

机译:在Botucatu医学院(HCFMB)-UNESP医院进行的1000例肾移植的评估及其多年来的发展

获取原文
           

摘要

Introduction: The progress in kidney transplantation has been evident over the years, as well as its benefits for patients. Objectives: To evaluate the 1.000 kidney transplants performed at the Botucatu Medical School University Hospital, subdividing the patients in different periods, according to the current immunosuppression, and evaluating the differences in graft and patient survival. Methods: Retrospective cohort analysis of the transplants performed between 06/17/87 to 07/31/16, totaling 1,046 transplants, subdivided into four different periods: 1) 1987 to 2000: cyclosporine with azathioprine; 2) 2001 to 2006: cyclosporine with mycophenolate; 3) 2007 to 2014: tacrolimus with antimetabolic; and 4) 2015 to 2016: tacrolimus with antimetabolic, with increased use of the combination of tacrolimus and mTOR inhibitors. Results: There was an increase in the mean age of recipients and increase in deceased donors and their age in the last two periods. There was a reduction in graft function delay, being 54.3% in the fourth period, compared to 78.8% in the first, p = 0.002. We found a reduction in acute rejection, being 6.1% in the last period compared to 36.3% in the first, p = 0.001. Urological complications and diabetes after transplantation were more frequent in the first two periods. The rates of cytomegalovirus infection were higher in the last two periods. There was an improvement in graft survival, p = 0.003. There was no difference in patient survival, p = 0.77 ( Figure 2 ). Conclusion: There was a significant increase in the number of transplants, with evolution in graft survival, despite the worsening in the profiles of recipients and donors.
机译:简介:多年来,肾脏移植取得了明显的进步,并为患者带来了好处。目的:评估在Botucatu医学院大学医院进行的1.000例肾脏移植,根据当前的免疫抑制情况,将患者分为不同时期,并评估移植物和患者生存率的差异。方法:回顾性队列分析在06/17/87至07/31/16期间进行,共1,046例移植,分为四个不同的时期:1)1987至2000年:环孢素与硫唑嘌呤; 2)环孢霉素联合硫唑嘌呤。 2)2001年至2006年:环孢霉素与霉酚酸酯; 3)2007年至2014年:他克莫司具有抗代谢作用;和4)2015年至2016年:他克莫司与抗代谢药合用,他克莫司和mTOR抑制剂的组合使用量增加。结果:在最近两个时期中,受助人的平均年龄有所增加,而死者的捐献者及其年龄也有所增加。移植功能延迟减少,在第四阶段为54.3%,而第一阶段为78.8%,p = 0.002。我们发现急性排斥反应减少,在最后一个时期减少了6.1%,而在第一时期减少了36.3%,p = 0.001。在前两个时期,泌尿外科并发症和移植后的糖尿病更为频繁。在最近两个时期,巨细胞病毒感染率较高。移植物存活率提高,p = 0.003。患者生存率无差异,p = 0.77(图2)。结论:尽管受者和供者的状况恶化了,但移植数目却随着移植存活的增加而显着增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号